Technical Analysis for EXEL - Exelixis, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Flat |
| Historical EXEL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| 50 DMA Resistance | Bearish | 2.95% | |
| MACD Bearish Centerline Cross | Bearish | 2.95% | |
| Bollinger Band Squeeze | Range Contraction | 2.95% | |
| Bearish Engulfing | Bearish | 1.55% | |
| Fell Below 200 DMA | Bearish | 1.55% | |
| Fell Below 20 DMA | Bearish | 1.55% | |
| Fell Below 50 DMA | Bearish | 1.55% | |
| Bollinger Band Squeeze | Range Contraction | 1.55% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above Previous Day's High | about 5 hours ago | |
| Up 3% | about 5 hours ago | |
| Rose Above 10 DMA | about 5 hours ago | |
| Up 2% | about 9 hours ago | |
| Rose Above 50 DMA | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/23/2021
Exelixis, Inc. Description
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Treatment Of Cancer Prostate Cancer Thyroid Tyrosine Kinase Glaxosmithkline Progressive Pivotal Protein Kinase Inhibitor Resistant Prostate Cancer Small Molecule Therapies Tyrosine Kinase Inhibitors Cyclopropanes Thyroid Cancer Metastatic Castration Resistant Prostate Cancer Receptor Tyrosine Kinase Daiichi Sankyo Tyrosine Kinases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.8 |
| 52 Week Low | 13.67 |
| Average Volume | 2,415,330 |
| 200-Day Moving Average | 22.49 |
| 50-Day Moving Average | 22.08 |
| 20-Day Moving Average | 22.48 |
| 10-Day Moving Average | 22.21 |
| Average True Range | 0.89 |
| ADX | 10.94 |
| +DI | 18.86 |
| -DI | 23.38 |
| Chandelier Exit (Long, 3 ATRs ) | 21.32 |
| Chandelier Exit (Short, 3 ATRs ) | 23.93 |
| Upper Bollinger Band | 23.53 |
| Lower Bollinger Band | 21.43 |
| Percent B (%b) | 0.41 |
| BandWidth | 9.36 |
| MACD Line | -0.04 |
| MACD Signal Line | 0.05 |
| MACD Histogram | -0.0917 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.53 | ||||
| Resistance 3 (R3) | 23.45 | 22.95 | 23.33 | ||
| Resistance 2 (R2) | 22.95 | 22.64 | 23.00 | 23.26 | |
| Resistance 1 (R1) | 22.63 | 22.45 | 22.79 | 22.71 | 23.19 |
| Pivot Point | 22.13 | 22.13 | 22.22 | 22.18 | 22.13 |
| Support 1 (S1) | 21.81 | 21.82 | 21.97 | 21.89 | 21.41 |
| Support 2 (S2) | 21.31 | 21.63 | 21.36 | 21.34 | |
| Support 3 (S3) | 20.99 | 21.31 | 21.28 | ||
| Support 4 (S4) | 21.07 |
